Prevalence and Risk Factors for School-Associated Transmission of SARS-CoV-2.


Journal

JAMA health forum
ISSN: 2689-0186
Titre abrégé: JAMA Health Forum
Pays: United States
ID NLM: 101769500

Informations de publication

Date de publication:
04 08 2023
Historique:
medline: 7 8 2023
pubmed: 4 8 2023
entrez: 4 8 2023
Statut: epublish

Résumé

School-associated SARS-CoV-2 transmission is described as uncommon, although the true transmission rate is unknown. To identify the SARS-CoV-2 secondary attack rate (SAR) in schools and factors associated with transmission. This cohort study examined the risk of school-based transmission of SARS-CoV-2 among kindergarten through grade 12 students and staff in 10 Massachusetts school districts during 2 periods: fall 2020/spring 2021 (F20/S21) and fall 2021 (F21). School staff collected data on SARS-CoV-2 index cases and school-based contacts, and SAR was defined as the proportion of contacts acquiring SARS-CoV-2 infection. SARS-CoV-2. Potential factors associated with transmission, including grade level, masking, exposure location, vaccination history, and Social Vulnerability Index (SVI), were analyzed using univariable and multivariable logistic regression models. For F20/S21, 8 school districts (70 schools, >33 000 students) were included and reported 435 index cases (151 staff, 216 students, and 68 missing role) with 1771 school-based contacts (278 staff, 1492 students, and 1 missing role). For F21, 5 districts (34 schools, >18 000 students) participated and reported 309 index cases (37 staff, 207 students, and 65 missing role) with 1673 school-based contacts (107 staff and 1566 students). The F20/S21 SAR was 2.2% (lower bound, 1.6%; upper bound, 26.7%), and the F21 SAR was 2.8% (lower bound, 2.6%; upper bound, 7.4%). In multivariable analysis, during F20/S21, masking was associated with a lower odds of transmission compared with not masking (odds radio [OR], 0.12; 95% CI, 0.04-0.40; P < .001). In F21, classroom exposure vs out-of-classroom exposure was associated with increased odds of transmission (OR, 2.47; 95% CI, 1.07-5.66; P = .02); a fully vaccinated vs unvaccinated contact was associated with a lower odds of transmission (OR, 0.04; 95% CI, 0.00-0.62; P < .001). In both periods, a higher SVI was associated with a greater odds of transmission. In this study of Massachusetts schools, the SAR for SARS-CoV-2 among school-based contacts was low during 2 periods, and factors associated with transmission risk varied over time. These findings suggest that ongoing surveillance efforts may be essential to ensure that both targeted resources and mitigation practices remain optimal and relevant for disease prevention.

Identifiants

pubmed: 37540523
pii: 2807905
doi: 10.1001/jamahealthforum.2023.2310
pmc: PMC10403780
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e232310

Références

J Infect. 2022 Mar;84(3):361-382
pubmed: 34953911
N Engl J Med. 2022 Nov 24;387(21):1935-1946
pubmed: 36351262
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):377-381
pubmed: 33735161
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):779-784
pubmed: 34043610
JAMA Netw Open. 2021 Jan 4;4(1):e2036462
pubmed: 33512520
Disaster Med Public Health Prep. 2022 May 02;17:e193
pubmed: 35492024
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):437-441
pubmed: 33764962
Pediatrics. 2022 Jun 1;149(6):
pubmed: 35260896
JAMA Intern Med. 2022 Jul 1;182(7):701-709
pubmed: 35486394
MMWR Morb Mortal Wkly Rep. 2022 Jun 10;71(23):770-775
pubmed: 35679198
Lancet Infect Dis. 2021 Mar;21(3):344-353
pubmed: 33306981
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1773-1777
pubmed: 34968371
Clin Infect Dis. 2022 Aug 24;75(1):e133-e143
pubmed: 35137014
JAMA Pediatr. 2021 Nov 1;175(11):1151-1158
pubmed: 34398179
MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):384-389
pubmed: 35271560
Am J Public Health. 2022 Nov;112(11):1584-1588
pubmed: 36108250
Pediatrics. 2022 Mar 1;149(3):
pubmed: 35194642
Pediatrics. 2021 May;147(5):
pubmed: 33688033
Pediatrics. 2022 May 1;149(5):
pubmed: 35437593
N Engl J Med. 2021 Sep 2;385(10):954-956
pubmed: 34289272
CMAJ Open. 2022 Apr 12;10(2):E357-E366
pubmed: 35414597
Pediatrics. 2022 May 1;149(5):
pubmed: 35132435

Auteurs

Sandra B Nelson (SB)

Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Harvard Medical School, Boston, Massachusetts.

Caitlin M Dugdale (CM)

Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Harvard Medical School, Boston, Massachusetts.
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston.

Isaac Ravi Brenner (IR)

Medical Practice Evaluation Center, Massachusetts General Hospital, Boston.

Allison Crawford (A)

Medical Practice Evaluation Center, Massachusetts General Hospital, Boston.

Alyssa Bilinski (A)

Department of Health Services, Policy and Practice and Department of Biostatistics, Brown School of Public Health, Providence, Rhode Island.

Duru Cosar (D)

Medical Practice Evaluation Center, Massachusetts General Hospital, Boston.

Nira R Pollock (NR)

Harvard Medical School, Boston, Massachusetts.
Department of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts.

Andrea Ciaranello (A)

Division of Infectious Diseases, Massachusetts General Hospital, Boston.
Harvard Medical School, Boston, Massachusetts.
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH